Loading...
OTCM
ENDV
Market cap31kUSD
Dec 05, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Endonovo Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:ENDV chart
P/E
P/S
3.17
EPS
Div Yield, %
Shrs. gr., 5y
278.80%
Rev. gr., 5y
-49.64%
Revenues
10k
-92.84%
60,00060,58547,76730,58122,89624,1924,2650083,263310,164165,79673,105135,355140,24210,043
Net income
-3m
L
-330,000-69,400-94,088-1,914,551-2,892,794-959,494-5,079,101-5,315,672-10,810,160-6,435,839-23,404,749-2,026,563-4,046,460-32,138,4876,924,594-2,797,297
CFO
100k
-17.55%
-80,0008,502-50,354-284,891-257,416-909,296-1,019,334-2,462,334-2,989,770-2,878,834-2,541,007-741,590-986,584-678,838121,870100,487

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
IPO date
Mar 09, 2012
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT